| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From Memory Assessment and Research Centre (Dr. Wilkinson), Moorgreen Hospital, Southampton, UK; Alzheimer’s Disease Center (Dr. Doody), Baylor College of Medicine, Houston, TX; National Ageing Research Institute (Dr. Helme), Parkville, Victoria, Australia; Austin and Repatriation Medical Centre (Dr. Taubman), Heidelberg, Victoria, Australia; Medical University of South Carolina (Dr. Mintzer), Alzheimer’s Research and Clinical Programs, North Charleston, SC; University of Western Ontario (Dr. Kertesz), St. Joseph’s Hospital, London, Ontario, Canada; and Eisai Inc. (Dr. Pratt), Teaneck, NJ.
Address correspondence and reprint requests to Dr. David Wilkinson, Memory Assessment and Research Centre, Moorgreen Hospital, Southampton SO30 3JB, UK; e-mail: david.wilkinson{at}wht.nhs.uk
Objective: To evaluate the efficacy and tolerability of donepezil in patients with vascular dementia (VaD).
Methods: Patients (n = 616; mean age, 75.0 years) with probable or possible VaD, according to National Institute of Neurological Disorders and Stroke–Association Internationale pour la Recherche en l’Enseignement en Neurosciences criteria, were randomized to receive donepezil 5 mg/day (n = 208), donepezil 10 mg/day (after 5 mg/day for the first 28 days) (n = 215), or placebo (n = 193) for 24 weeks.
Results: Seventy-six percent of the patients enrolled had probable VaD. A total of 75.3% of the 10 mg donepezil group and 80.8% of the 5 mg group completed the study compared with 83.4% of the placebo group. Both donepezil-treated groups showed improvements in cognitive function on the Alzheimer’s Disease Assessment Scale–cognitive subscale compared with placebo, with a mean endpoint treatment difference, as measured by the change from baseline score, of approximately 2 points (donepezil 5 mg, -1.65 [p = 0.003]; 10 mg, -2.09 [p = 0.0002]). Greater improvements on the Clinician’s Interview-Based Impression of Change–plus version were observed with both donepezil groups than with the placebo group (overall donepezil treatment vs placebo p = 0.008); 25% of the placebo group showed improvement compared with 39% (p = 0.004) of the 5 mg group and 32% (p = 0.047) of the 10 mg group. Withdrawal rates due to adverse events were low (placebo, 8.8%; donepezil 5 mg, 10.1%; 10 mg, 16.3%).
Conclusions: Donepezil-treated patients demonstrated significant improvements in cognition and global function compared with placebo-treated patients, and donepezil was well tolerated.
This article has been cited by other articles:
|
|
 |
|
  A. Qaseem, V. Snow, J. T. Cross Jr., M. A. Forciea, R. Hopkins Jr., P. Shekelle, A. Adelman, D. Mehr, K. Schellhase, D. Campos-Outcalt, et al. Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians Ann Intern Med, March 4, 2008; 148(5): 370 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Raina, P. Santaguida, A. Ismaila, C. Patterson, D. Cowan, M. Levine, L. Booker, and M. Oremus Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline Ann Intern Med, March 4, 2008; 148(5): 379 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Modrego, C. Rios, J. M. Perez Trullen, J. M. Errea, M. J. Garcia-Gomara, and S. Sanchez The Cerebrovascular Pathology in Alzheimer's Disease and Its Influence on Clinical Variables American Journal of Alzheimer's Disease and Other Dementias, March 1, 2008; 23(1): 91 - 96. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Schneider, Z. Arvanitakis, W. Bang, and D. A. Bennett Mixed brain pathologies account for most dementia cases in community-dwelling older persons Neurology, December 11, 2007; 69(24): 2197 - 2204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Auchus, H. R. Brashear, S. Salloway, A. D. Korczyn, P. P. De Deyn, C. Gassmann-Mayer, and For the GAL-INT-26 Study Group Galantamine treatment of vascular dementia: A randomized trial Neurology, July 31, 2007; 69(5): 448 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Burns and J. O'Brien Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol, November 1, 2006; 20(6): 732 - 755. [Abstract] [PDF]
|
|
|
|
 |
|
 J. T. O'Brien Vascular Cognitive Impairment Am J Geriatr Psychiatry, September 1, 2006; 14(9): 724 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Langa, N. L. Foster, and E. B. Larson Mixed Dementia: Emerging Concepts and Therapeutic Implications JAMA, December 15, 2004; 292(23): 2901 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Krupp, C. Christodoulou, P. Melville, W. F. Scherl, W. S. MacAllister, and L. E. Elkins Donepezil improved memory in multiple sclerosis in a randomized clinical trial Neurology, November 9, 2004; 63(9): 1579 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Sachdev, H. Brodaty, M. J. Valenzuela, L. Lorentz, and A. Koschera Progression of cognitive impairment in stroke patients Neurology, November 9, 2004; 63(9): 1618 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Rockwood Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, May 1, 2004; 75(5): 677 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Erkinjuntti, G. Roman, S. Gauthier, H. Feldman, and K. Rockwood Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment Stroke, April 1, 2004; 35(4): 1010 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Bowler Vascular Cognitive Impairment Stroke, February 1, 2004; 35(2): 386 - 388. [Full Text] [PDF]
|
|
|
|
 |
|
 Donepezil for Vascular Dementia Journal Watch Psychiatry, November 20, 2003; 2003(1120): 17 - 17. [Full Text]
|
|
|
|
|
|
S. Black, G. C. Roman, D. S. Geldmacher, S. Salloway, J. Hecker, A. Burns, C. Perdomo, D. Kumar, and R. Pratt Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial Stroke, October 1, 2003; 34(10): 2323 - 2330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Donepezil for Vascular Dementia Journal Watch (General), September 26, 2003; 2003(926): 1 - 1. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
